To view the publications, please select the year of publication first followed by clicking on the (+) sign to access the full list of publications for that year. When you are ready to view the publications for another year, please click on the (-) sign to return to the initial default display.?
Publications: 2003
|
Nam RK, Zhang WW, Trachtenberg J, Jewett MA, Emami M, Vesprinin D, Chu W, Ho M, Sweet J, Toi A,?Pollak M, Narod SA. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.?Cancer Epidemiol Biomarkers Prev?12: 1429-37, 2003. |
|
|
Pollak M, Foulkes W. Challenges to cancer control by screening.?Nature Reviews Cancer?3: 297-303, 2003. |
|
|
Giovannucci E,?Pollak M,?Liu Y, Platz EA,?Majeed N, Rimm EB, Willet WC. Nutritional predictors of insulin-like growth factor-I and their relationships to cancer in men.?Cancer Epidemiology Biomarkers & Prevention?12: 84-89, 2003. |
|
|
Saydah SH, Platz EA, Rifai N,?Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk.?Cancer Epidemiology Biomarkers & Prevention?12: 412-418, 2003. |
|
|
Schernhammer ES, Hankinson SE, Hunter DJ,?Blouin MJ,?Pollak MN. Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk.?International Journal of Cancer?107: 60-64, 2003. |
|
|
Nomura AM, Stemmermann GN, Lee J,Pollak MN. Serum Insulin-like Growth Factor 1 and Subsequent Risk of Colorectal Cancer among Japanese-American Men.?American Journal of Epidemiology?158: 424-431, 2003. |
|
|
Woodson K, Tangrea JA,?Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.?Cancer Research?63: 3991-4, 2003. |
|
|
Ismail AH,Pollak M, Behlouli H, Tanguay S, B¨¦gin LR, Aprikian AG. Serum insulin-like growth factor (IGF) ¨C 1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples.?British Journal of Urology International?92: 699-702, 2003. |
|
|
VanHouten JN, Dann P, Stewart AF, Watson CJ, Karaplis AC,Pollak M, Wysolmerski JJ. Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation.?The Journal of Clinical Investigation?112: 1429-1436, 2003. |
|
|
Hussain M, Banerjee M, Sarkar FH, Djuric Z,?Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O. Soy isoflavones in the treatment of prostate cancer.?Nutri Cancer?47: 111-7, 2003. |
Publications: 2002
|
Ismail AH,?Pollak M, Behlouli H, Tanguay S, B¨¦gin LR, Aprikian AG. Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy.?The Journal of Urology?168: 2426-30, 2002. |
|
|
Camirand A, Lu YH,?Pollak M.?Co-targeting HER2/erbB2 and IGF-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.?Medical Science Monitor?8: BR521-526, 2002. |
|
|
Levitt RJ,?Pollak M.?Insulin-like growth factor-I antagonizes the anti-proliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells.?Cancer Research?62: 7372-7376, 2002. |
|
|
Kucuk O, Sarkar FH, Djuric Z, Sakr W,?Pollak MN, Khachik F, Banerjee M, Bertram JS, Wood DP Jr. Effects of lycopene supplementation in patients with localized prostate cancer.?Experimental Biology and Medicine?227: 881-885, 2002. |
|
|
Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X,?Pollak M.?Serum Insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: A case-control study nested in the beta-carotene and retinol efficacy trial cohort.?Cancer Epidemiology Biomarkers & Prevention?11: 1413-1418, 2002. |
|
|
Giovannucci E, Haiman CA, Platz EA, Hankinson SE,?Pollak MN.?Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma.?Cancer Epidemiology Biomarkers & Prevention?11: 1509-1510, 2002. |
|
|
Deitel K, Dantzer D, Ferguson P,?Pollak M, Beamer W, Andrulis I, Bell R. Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation.?Journal of Surgical Oncology?81: 75-79, 2002. |
|
|
Holmes MD,?Pollak MN, Hankinson SE. Lifestyle correlates of plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 concentrations.?Cancer Epidemiology,?Biomarkers & Prevention?11: 862-867, 2002. |
|
|
Holmes MD,?Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 concentrations.?Cancer Epidemiology,?Biomarkers & Prevention?11: 852-861, 2002. |
|
|
Kucuk O, Sarkar FH, Sakr W, Khachik F, Djuric Z, Banerjee M,?Pollak MN, Bertram JS, Wood DP. Lycopene in the treatment of prostate cancer.?Pure and Applied Chemistry?74: 1443-50, 2002. |
|
|
Missmer SA, Haiman CA, Hunter DJ, Willett WC, Colditz GA, Speizer FE,?Pollak MN, Hankinson SE. A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer.?International Journal of Cancer?100: 332-6, 2002. |
|
|
Toppmeyer D, Seidman AD,?Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.?Clinical Cancer Research?8: 670-8, 2002. |
|
|
Giovannucci E,?Pollak M.?Risk of cancer after growth-hormone treatment. [editorial]?Lancet?360: 268-9, 2002. |
|
|
Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM,?Pollak M, Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.?Journal of the National Cancer Institute?94: 1099-1106, 2002. |
Publications: 2001
|
Lu Y,?Zi X, Zhao Y, Mascarenhas D,?Pollak M.?Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).?Journal of the National Cancer Institute?93: 1852-1857, 2001.? [see also?favourable editorial comment?[.pdf] -?J Natl Cancer Inst?93: 1830-2, 2001] |
|
|
Ma J, Giovannucci E,?Pollak M, Chan JM, Gaziano JM, Willett W, Stampfer MJ. Milk intake, circulating levels of insulin like growth factor-I and risk of colorectal cancer in men.?Journal of the National Cancer Institute?93: 1330-1336, 2001. |
|
|
Chan TW,?Pollak M,?Huynh H.?Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780.?Clinical Cancer Research?7: 2545-2554, 2001. |
|
|
Kucuk O, Sarkar FH, Sakr W, Djuric Z,?Pollak M N, Khachik Y, Banerjee M, Grignon D, Bertram JS, Crissman JD, Pontes EJ, Wood DP Jr. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy.?Cancer Epidemiology Biomarkers & Prevention?10: 861-8, 2001. |
|
|
Thorner M and writing committee (including?Pollak M). Critical evaluation of the safety of recombinant human growth hormone administration: Statement from the growth hormone research society.?Journal of Clinical Endocrinology & Metabolism?86:1868-1870, 2001. |
|
|
Nickerson T, Chang F, Tran C, Lorimer D, Smeekens SP, Sawyers CI,?Pollak M.?In vivo of LAPC-9 and LNCaP cancer models to androgen independence is associated with increased expression of IGF-I and IGF-IR.?Cancer Research?61: 6276-6280, 2001. |
|
|
He B, Deckelbaum RA, Miao D, Lipman ML,?Pollak M, Goltzman D, Karaplis AC. Tissue-Specific targeting of the Pthrp gene: The generation of mice with floxed alleles.?Endocrinology?142: 2070-7, 2001. |
|
|
Chokkalingam AP,?Pollak M, Fillmore C, Gao Y, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr, Hsing AW. Insulin-like growth factors and prostate cancer: a population-based cased-control study in China.?Cancer Epidemiology Biomarkers & Prevention?10:421-7, 2001. |
|
|
Pollak M,?Blouin M-J, Jian-Chun Z, Kopchick JJ. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist.?British Journal of Cancer?85: 428-430, 2001. |
|
|
Tolcher AW, Kennedy A, Padley RJ,?Majeed N,?Pollak M, Kantoff PW. Other novel agents: Rationale and current status as chemopreventive agents.?Urology?57: 86-9, 2001. |
|
|
Chokkalingam AP, McGlynn KA, Gao Y,?Pollak M, Deng J, Sesterhenn IA, Mostofi FK, Fraumeni JF Jr, Hsing AW. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China.?Cancer Research?61: 4333-6, 2001. |
|
|
Pollak M.?Insulin-like growth factors (IGFs) and prostate cancer.?Epidemiologic Reviews?23: 59-66, 2001. |
|
|
Trojan D, Collet J,?Pollak M, Shapiro S, Jubelt B, Miller R, Agre J, Munsat TL, Hollander D, Tandan R, Robinson A, Finch L, Ducruet T, Cashman N. Serum insulin-like growth factor-I (IGF-I) does not correlate positively with isometric strength, fatigue, and quality of life in post-polio syndrome.?Journal of the Neurological Sciences?182:107-115, 2001. |
|
|
Jernstr?m H, Chu W, Vesprini D,?Tao Y,?Majeed N, Deal C,?Pollak M, and Narod SA. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for pre-menopausal breast cancer risk.?Molecular Genetics and Metabolism?72: 144-54, 2001. |
|
|
Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M,?Pollak M.?Novel promoter polymorphism in IGFBP3: Correlation with serum levels and interaction with known regulators.?Journal of Clinical Endocrinology & Metabolism?86: 1274-80, 2001. |
|
|
Jernstr?m H, Wilkin F, Deal C, Chu W,?Tao Y,?Majeed N, Narod S, Hudson T,Pollak M.?Genetic and non-genetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in healthy premenopausal women.?Cancer Epidemiology Biomarkers & Prevention?10: 377-384, 2001. |